In this issue of JAMA Oncology, Palma et al1 present ORATOR2, a prospective randomized clinical trial designed to test the best of nonsurgical and surgical deintensification strategies in low-risk human papillomavirus (HPV)–positive oropharynx squamous cell cancer (OPSCC). The results were published after deaths in the surgical arm led to early closure of the trial.
Teckie S, Gross ND. The ORATOR Trials Have Spoken—Where Do We Go From Here? JAMA Oncol. 2022;8(6):851–852. doi:10.1001/jamaoncol.2022.0461
Artificial Intelligence Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.